Beyond the vial: Rethinking IRT for cell and gene therapy. Cell and gene therapies change the fundamental unit of clinical supply. In a conventional study, supply planning may focus on having the right product at the right site. In cell and gene therapy, the product is inseparable from the patient, treatment schedule, manufacturing and release status, storage conditions, location and chain of identity. The unit of supply becomes an interconnected treatment journey centred on far more than a vial. That was the central theme of ICON's presentation, Beyond the vial: IRT's role in controlling patient-product readiness across the CGT journey, delivered by Alyssa Gilliam, VP, IRT & CSM, at IRT & RTSM 2026. The session explored how interactive response technology (IRT) can help study teams manage the decisions and dependencies surrounding treatment readiness without replacing specialist manufacturing, quality or logistics systems. For ICON, this discussion also points to how its IRT platform, Flex Advantage, can work within a connected CGT operating model, using trusted information from specialist platforms to support enrolment, treatment scheduling, product allocation and other controlled study actions. Different therapies require different controls. The operational requirements of autologous and allogeneic therapies may differ significantly. In an autologous therapy, material collected from a patient is used to create a treatment unique to that individual. This creates a closed loop in which identity continuity, coupled scheduling and an individual exception pathway become essential controls. Allogeneic therapies introduce a different model. Supply may originate from healthy donors or manufacturing batches and be allocated across multiple recipients. This places greater emphasis on donor, batch and lot traceability, attribute-aware inventory management and safeguards that prevent an unsuitable product or variant from reaching a patient. In both models, the challenge extends beyond knowing where inventory is. The study must maintain the connection between identity, time, condition, place and exception status throughout the treatment journey. Collection, manufacture, release, shipment and treatment dates are interdependent, and product condition, site qualifications, receiving hours and storage capacity can all affect whether the next step may safely proceed. From inventory visibility to orchestration. As these dependencies multiply, the role of IRT must evolve. Study teams need to define the information IRT must hold, the decisions it must support, the communications it must trigger and the evidence it must retain. This evolution keeps manufacturing, quality, condition-monitoring and logistics capabilities within the specialist systems designed to manage them. Applications such as ICON's Advanced Therapy Orchestration Manager (ATOM) can provide visibility and management of participant and product logistics, while the IRT layer uses selected events to trigger controlled study actions. Depending on the event and operating model, IRT can then direct the appropriate user to proceed, hold, notify or escalate. The distinction matters. Multiple systems can contribute authoritative information while retaining clearly defined responsibilities. In one potential model, ATOM manages authoritative product, manufacturing, release, shipment and detailed custody information, while Flex Advantage supports the study journey through enrolment, scheduling, product assignment, site receipt and study oversight. The precise boundary must be defined for each study, including which system owns each event, who can make a decision and what action should be presented to each role. Product arrival is one step towards treatment readiness. Receipt of the product at the site is an important milestone within a broader readiness assessment. Before dosing, study teams may need to confirm patient and site readiness, identity continuity, manufacturing and release status, transportation conditions and the resolution of any discrepancies. The final decision may then be to proceed, hold or escalate. Recording receipt captures one event; controlling readiness requires a decision supported by verified information across the patient-product journey. A connected approach can bring selected authoritative events from ATOM into Flex Advantage, giving authorised study and site users the information needed for the next controlled action without duplicating the underlying manufacturing or logistics record. The design principle is to exchange the minimum information required to schedule, release, receive, administer and reconcile treatment. Design around real-world exceptions. Effective orchestration begins early. IRT, clinical supply, quality, manufacturing, logistics and site teams should work together to determine how the journey will be controlled. The presentation set out five areas for early design: * Map the journey by defining persistent identifiers, custody evidence and ownership across systems. * Define the controls governing holds, quarantine, readiness gates and role-based actions, with clear boundaries between product authority and IRT-supported study decisions. * Design the event logic connecting schedules, trusted events, alerts and reconciliation. * Test exceptions involving identity, release, condition, timing and system downtime. * Operate and adapt by monitoring system health, governing change and rehearsing exception recovery. The principle is straightforward: build failed hand-offs and unavailable interfaces into the design from the outset, alongside the ideal pathway. Making limited supply decision-ready. The presentation also demonstrated IRT's potential value in an allogeneic cell therapy study involving limited, high-value inventory, a multi-country supply chain and dose-escalation cohorts. Configurable IRT capabilities available through Flex Advantage, including enrolment, cohort-assigned randomisation, product management, reporting and system integrations, provide a foundation for this type of study design. Within a connected CGT operating model, those capabilities could support product allocation, inventory visibility and cohort controls while trusted events from specialist systems inform treatment-readiness decisions. The example illustrates how IRT can help turn distributed information into controlled and actionable study decisions, provided its role and boundaries are established clearly. The destination: decision-ready orchestration. For cell and gene therapy studies, visibility is only the starting point. Teams must know whether the patient-product journey can move forward and what must happen when progress is blocked. A decision-ready approach to IRT can help: * Prove identity and custody at critical hand-offs. * Orchestrate dates, milestones and readiness across systems. * Protect patients and studies by preventing progression while product or patient conditions remain unresolved. * Recover through predefined exception and downtime pathways. By connecting information about the patient, product, place, time, condition and decision status, IRT can support more controlled decisions in complex therapy studies. It brings the right information from specialist systems to the right person when a study decision must be made. That is how IRT moves beyond the vial. In this section.

Icon (NASDAQ:ICLR) stock rating upgraded by UBS Group. Icon (NASDAQ:ICLR - Get Free Report) was upgraded by analysts at UBS Group to a "hold" rating in a research report issued on Wednesday, Zacks reports. ICLR has been the subject of a number of other research reports. Royal Bank Of Canada raised shares of Icon from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $126.00 to $185.00 in a research report on Thursday, June 25th. Robert W. Baird set a $194.00 price objective on shares of Icon in a research note on Friday, July 31st. Truist Financial reissued a "buy" rating and set a $209.00 target price (up from $207.00) on shares of Icon in a research note on Friday, July 31st. TD Cowen boosted their target price on shares of Icon from $164.00 to $197.00 and gave the company a "buy" rating in a report on Thursday, June 25th. Finally, Citigroup cut their price target on shares of Icon from $180.00 to $175.00 and set a "neutral" rating on the stock in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Icon presently has an average rating of "Hold" and a consensus target price of $172.40. Icon trading down 4.8%. ICLR opened at $161.85 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The company's 50 day moving average price is $167.35 and its two-hundred day moving average price is $144.42. The firm has a market capitalization of $12.39 billion, a price-to-earnings ratio of 37.99, a PEG ratio of 7.87 and a beta of 1.24. Icon (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.26 earnings per share. As a group, research analysts predict that Icon will post 9.56 earnings per share for the current year. Insider activity at Icon. In related news, Director Ronan Murphy sold 5,005 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $875,875.00. Following the transaction, the director directly owned 3,847 shares of the company's stock, valued at $673,225. This represents a 56.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ciaran Murray sold 2,677 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33. Following the transaction, the director directly owned 20,452 shares in the company, valued at approximately $3,360,059.08. This represents a 11.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 22,796 shares of company stock worth $3,887,139. Corporate insiders own 44.00% of the company's stock. Hedge funds weigh in on Icon. Several institutional investors have recently made changes to their positions in ICLR. Abound Financial LLC acquired a new stake in shares of Icon in the 4th quarter valued at about $54,000. GAMMA Investing LLC raised its stake in Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company's stock worth $68,000 after buying an additional 69 shares during the period. Global Retirement Partners LLC boosted its holdings in Icon by 308.2% in the fourth quarter. Global Retirement Partners LLC now owns 547 shares of the medical research company's stock worth $100,000 after acquiring an additional 413 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Icon by 120.0% in the second quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company's stock valued at $107,000 after acquiring an additional 336 shares during the period. Finally, Blue Trust Inc. grew its stake in Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company's stock valued at $73,000 after acquiring an additional 444 shares during the period. Institutional investors and hedge funds own 95.61% of the company's stock. About Icon. ICON plc is a global contract research and clinical development organization headquartered in Dublin, Ireland. The company provides outsourced services to pharmaceutical, biotechnology, medical device and government organizations, supporting the development and commercialization of healthcare products. Its services span clinical trial management, clinical and regulatory consulting, data management, biostatistics, medical writing, pharmacovigilance, laboratory services, medical imaging and commercialization support. Further reading. Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Icon PLC shares rose 2.5% in the month following its latest earnings report, underperforming the S&P 500. The company posted second-quarter adjusted earnings per share of $2.56, down 21.5% year-over-year and missing analyst estimates by 0.4%. Total revenues increased 1.4% to $2.06 billion, beating consensus estimates by 3.5%. On a constant-currency basis, revenues grew 0.4%. Icon reiterated its full-year 2026 guidance, expecting revenues between $7.85 billion and $8.15 billion. Adjusted earnings per share are forecast in the range of $10.00 to $11.00. Since the earnings release, analyst estimates have trended downward. The stock currently holds a Zacks Rank of Hold, suggesting expected in-line returns in coming months.